TETRAHYDROISOQUINOLINE COMPOUND, ITS PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION CONTAINING SUCH A COMPOUND, AND ITS USE Russian patent published in 2023 - IPC C07D401/06 C07D401/08 C07D401/12 C07D471/04 C07D217/06 C07D217/14 C07D221/04 A61K31/4725 A61P29/00 A61P11/00 A61P25/14 

FIELD: medicine.

SUBSTANCE: invention relates to a compound of tetrahydroisoquinoline of the general formula (I), which has a property of a type 4 phosphodiesterase inhibitor, a method for its production, and a pharmaceutical composition based on it for the prevention, treatment, or adjuvant treatment of immune or inflammatory diseases caused by the activity or expression of PDE4. In the general formula (I), a chiral carbon atom C* independently has type S, type R, or a combination thereof; n = 1; X is -CH₂- ; Y is a binding group selected from linear or branched C1-C6 alkylene, -CH₂O-, -CH₂NH-, , , or ; each of R₁ and R₂ groups is independently selected from a group consisting of deuterium, hydroxyl, halogen, substituted or unsubstituted linear or branched C1-C6 alkoxy, substituted or unsubstituted C3-C7 cycloalkoxy, substituted or unsubstituted C3-C7 cycloalkylmethoxy, benzyloxy, carboxy-substituted linear C2-C8 alkoxy, N,N-dimethylamine-substituted linear C2-C8 alkoxy, COOR₅, or CONR₅R₆; the substitute is selected from deuterium or halogen; each of R₃ groups is selected from following groups, which are not substituted or substituted 1-2 substitutes: -C(O)-(5-7-element heteroaryl), -C(O)-(4-7-element heterocyclic group), -C1-C4 acyl, -CHO, R₇SO₂-, NH₂(CH₂)_mSO₂-, R₇SO₂(CH₂)_m-, R₇O(CH₂)_mCO-, R₇OCO(CH₂)_m-, difluoromethyl, benzenesulfonyl, 5-7-element heteroarylsulfonyl; where each of heterocyclic groups or heteroaryl groups contains from 1 to 2 heteroatoms selected from oxygen, sulfur, or nitrogen; and each of substitutes is independently selected from halogen, linear or branched C1-C6 alkoxy, trifluoromethyl group, C0-C4 sulfonyl group; each of R₅, R₆, and R₇ groups is independently selected from hydrogen, substituted or unsubstituted linear or branched C1-C4 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C6-C10 aryl, in which the substitute is selected from halogen; m is selected from 0, 1, or 2; R₄ is a group, which is not substituted or substituted with 1-2 substitutes and is selected from 5-12-element heteroaryl group; where each of the specified heteroaryls contains from 1 to 2 heteroatoms selected from oxygen, sulfur, or nitrogen; each of the specified substitutes is independently selected from deuterium, halogen, linear or branched C1-C6 alkyl, linear or branched C1-C6 alkoxy, linear or branched C1-C6 alkylcarbonyloxy, cyano, nitro, hydroxy, amino, hydroxymethyl, trifluoromethyl, trifluoromethoxy, difluoromethyl, difluoromethoxy, COOR₅.

EFFECT: provision of a compound of the general formula (I), having properties of a type 4 phosphodiesterase inhibitor.

11 cl, 7 tbl, 234 ex